Referencias►
1.
Harris WS. N-3 fatty acids and serum lipoproteins: human studies.
Am J Clin Nutr. 1997;65(Suppl 5):S1645 - S1654.
2.
van Dam M, Stalenhoef AF, Wittekoek J, et al. Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia: a comparison with gemfibrozil.
Clin Drug Invest. 2001;21:175 - 181.
3.
Montori VM, Farmer A, Wollan PC, et al. Fish oil supplementation in type 2 diabetes: a quantitative systematic review.
Diabetes Care. 2000;23:1407 - 1415.
4.
Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Heart. 2001;85:544 - 548.
5.
Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.
Am J Clin Nutr. 2000;71:1085 - 1094.
6.
Rambjor GS, Walen AI, Windsor SL Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans.
Lipids. 1996;31(Suppl):S45 - S49.
7.
Agren JJ, Hanninen O, Julkunen A, et al. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels.
Eur J Clin Nutr. 1996;50:765 - 771.
8.
Childs MT, King IB, Knopp RH. Divergent lipoprotein responses to fish oils with various ratios of eicosapentaenoic acid and docosahexaenoic acid.
Am J Clin Nutr. 1990;52:632 - 639.
9.
Davidson MH, Maki KC, Kalkowski J, et al. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.
J Am Coll Nutr. 1997;16:236 - 243.
10.
Leigh-Firbank EC, Minihane AM, Minihane AM, et al. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses.
Br J Nutr. 2002;87:435 - 445.
11.
Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids.
N Engl J Med. 1995;333:276 - 281.
12.
Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.
Atherosclerosis. 1984;50:73 - 83.
13.
Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinaemic patients after treatment with pantethine: a crossover, double-blind trial versus placebo.
Curr Ther Res. 1983;33:1091 - 1097.
14.
Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.
Int J Clin Pharmacol Ther Toxicol. 1986;24:630 - 637.
15.
Rubba R, Postiglione A, De Simone B, et al. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia.
Curr Ther Res. 1985;38:719 - 727.
16.
Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol.
Curr Ther Res. 1984;36:314 - 322.
17.
Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.
Metabolism. 1992;41:768 - 771.
18.
Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.
Diabetes Care. 1994;17:1449 - 1452.
19.
Rabinowitz MB, Gonick HC, Levin SR, Davidson MB. Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men.
Diabetes Care. 1983;6:319 - 327.
20.
Thomas VL, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors.
Biol Trace Elem Res. 1996;55:297 - 305.
21.
Uusitupa MI, Kumpulainen JT, Voutilainen E, et al. Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics.
Am J Clin Nutr. 1983;38:404 - 410.
22.
Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol in apolipoprotein fractions in human subjects.
West J Med. 1990;152:41 - 45.
23.
Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects.
Diabetes. 1980;29:919 - 925.
24.
Offenbacher EG, Rinko CJ, Pi-Sunyer FX. The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects.
Am J Clin Nutr. 1985;42:454 - 461.
25.
Roeback JR Jr, Hla KM, Chambless LE, Fletcher RH. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial.
Ann Intern Med. 1991;115:917 - 924.
26.
Wilson BE, Gondy A. Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects.
Diabetes Res Clin Pract. 1995;28:179 - 184.
27.
Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double-blind, placebo-controlled study.
J Assoc Physicians India. 2001;49:1057 - 1061.
28.
Earnest CP, Almada AL, Mitchell TL. High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women.
Clin Sci
(Colch). 1996;91:113 - 118.
29.
Asgary S, Naderi GH, Sarrafzadegan N, et al. Antihypertensive and antihyperlipidemic effects of Achillea wilhelmsii.
Drugs Exp Clin Res. 2000;26:89 - 93.
30.
Babu JR, Sundravel S, Arumugam G, et al. Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels.
Cancer Lett. 2000;151:1 - 5.